# A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

> **NCT00747318** · PHASE3 · COMPLETED · sponsor: **SkyePharma AG** · enrollment: 280 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** SKP FlutiForm HFA pMDI

## Key facts

- **NCT ID:** NCT00747318
- **Lead sponsor:** SkyePharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2011-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747318, "A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00747318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*